The following is an overview of some of the latest research on the new coronavirus and efforts to find treatments and vaccines for COVID-1
Delaying the second dose of Pfizer / BioNTech increases antibodies in the elderly
Delaying the second dose of Pfizer / BioNTech (PFE.N), the COVID-19 vaccine, above the initially recommended three-week difference used by companies in clinical trials appears to elicit a stronger antibody response in the elderly, British researchers found. Shortly after the vaccine became available, health officials in the UK recommended that the second dose be given 12 weeks after the first to allow more people to be protected with the first dose early. In a new article seen by Reuters and expected to appear on medRxiv on Friday before a peer review, researchers found that among 175 people aged 80 to 99, those who received their second dose at 12 weeks had answers. of antibodies that are 3.5 times higher than those who received it after three weeks. Antibodies are just one part of the immune system, and vaccines also generate T cells that fight infections. Peak T cell responses were higher in the group with a three-week dose interval, and the authors warned against drawing conclusions about how protected individuals were based on which dosing schedule they received. (https://reut.rs/3wjPK9B)
The impact of obesity on the risks of COVID-19 may be greater in men
The known increased risk of severe COVID-19 and obesity-related death may be even more pronounced for men than for women, new data show. The researchers studied 3,530 hospitalized COVID-19 patients with a mean age of 65 years, including 1,469 who were obese. In men, moderate obesity is associated with a significantly higher risk of developing a serious illness that requires mechanical respiratory care and death from COVID-19. The threshold for moderate obesity is a body mass index (BMI) of 35. In a 5-foot, five-inch tall (1.65 m) adult, which would correspond to a weight of 95 kilograms.In women, however, only BMI of 40 or more, indicating severe obesity, is associated with increased risks.In a report published in the European Journal of Clinical Microbiology & Infectious Diseases, researchers note that while obesity is known to be associated with whole-body inflammation, levels of inflammatory Patients’ proteins do not seem to explain the link between obesity and severe disease, so far they have concluded that “special attention should be paid” to protecting obese patients from coronavirus, “with priority given to access to vaccination, telecommuting, telemedicine and others. measures, given the higher risk of adverse effects after being diagnosed with COVID-19. “(https://bit.ly/3eO6GiA)
COVID-19 tests are low among symptomatic Americans
Sick Americans seem to miss out on opportunities to be tested for coronavirus and thus unknowingly spread the infection to their communities, new research shows. Of the 37,000 adults in the United States who participated in a survey of smartphone apps between March and October 2020, nearly 2,700 reported at least one episode of fever and chills. But according to a report published in the JAMA Network Open, only a small number reported receiving a COVID-19 test within seven days of the onset of the disease. Initially, as tests become more accessible, the numbers improve. At the beginning of April 2020, less than 10% of study participants reporting high-grade illness received test results within a week. By the end of July, this share had increased to 24.1%. In the summer and fall, as tests become easier to find, the number of sick participants who report being tested remains the same. By the end of October, only 26% reported receiving a test result within a week of febrile illness. “It’s shocking to me that when people have a fever, they still don’t get tested,” said co-author Dr. Mark Pletcher of the University of California, San Francisco. “Tests are easy to perform. People can have a coronavirus, they can spread it to their friends and neighbors, and they don’t get tested.” (https://bit.ly/2QUyMzf)
Open https://tmsnrt.rs/3c7R3Bl in an external browser for the Reuters schedule for vaccines under development.
Our standards: Thomson Reuters’ principles of trust.